FindMyKOL

Top experts by indication / Ophthalmology

Most active experts in Macular Degeneration (AMD)

2026 edition, data as of October 26, 2026

361 key opinion leaders in the directory are tagged to Macular Degeneration (AMD). The tables below rank them by one public measure each: registered trials, citations, NIH awards and congress contributions. Each is a count from a named source, not a judgment about the person, and every row links a profile where the count can be checked.

Most registered trials

Registered clinical trials in this indication on which the person is a listed investigator, counted from ClinicalTrials.gov. 65 of the 361 people tagged to this indication have this count on record; the 25 highest are listed. Source: ClinicalTrials.gov.

#Experttrials
1Emily ChewNational Eye Institute, MD10 trials
2Peter CampochiaroWilmer Eye Institute, MD7 trials
3Arshad KhananiSierra Eye Associates, NV7 trials
4Wai WongTiresias Biopharma Consulting, MD6 trials
5Raj MaturiIndiana University School of Medicine, IN5 trials
6Jason SlakterNYU Grossman School of Medicine, NY5 trials
7Robert SnyderAZ4 trials
8Charles WykoffRetina Consultants of Texas, TX4 trials
9Neil BresslerWilmer Eye Institute, MD4 trials
10Dante PieramiciCalifornia Retina Consultants, CA4 trials
11David EichenbaumRetina Vitreous Associates of Florida, FL4 trials
12Jason HsuPA3 trials
13David BrownTX3 trials
14Anne FungPacific Eye Associates, CA3 trials
15Robert AveryNM3 trials
16Jeremy KeenanUniversity of California, San Francisco, CA3 trials
17Dilsher DhootCalifornia Retina Consultants, CA3 trials
18Susanna ParkUniversity of California, Davis, CA3 trials
19Scott CousinsDuke Medical Center, NC3 trials
20Tiarnan KeenanNational Eye Institute, MD3 trials
21Brandon BusbeeTennessee Retina, TN3 trials
22Joel PearlmanVitreo-Retinal Medical Group, CA3 trials
23Richard RosenNY2 trials
24Hugo Quiroz-MercadoCO2 trials
25Gaurav ShahCA2 trials

Most cited

Citations to the person's whole published record in OpenAlex, not only their work in this indication, among the people with at least two registered trials in it. 21 of the 361 people tagged to this indication have at least 2 registered trials in it and this count on record; the 21 highest are listed. Source: OpenAlex.

#Expertcitations
1Emily ChewNational Eye Institute, MD76,887 citations
2Peter CampochiaroWilmer Eye Institute, MD42,532 citations
3Charles WykoffRetina Consultants of Texas, TX23,504 citations
4Allen HoWills Eye Hospital, PA19,340 citations
5Paul BernsteinJohn A. Moran Eye Center, UT19,147 citations
6Wai WongTiresias Biopharma Consulting, MD15,331 citations
7Karl CsakyRetina Foundation of the Southwest, TX15,096 citations
8Carl RegilloSidney Kimmel Medical College at Thomas Jefferson University, PA14,493 citations
9Dante PieramiciCalifornia Retina Consultants, CA11,358 citations
10Jeremy KeenanUniversity of California, San Francisco, CA9,819 citations
11Scott CousinsDuke Medical Center, NC9,289 citations
12Tiarnan KeenanNational Eye Institute, MD6,492 citations
13Joel PearlmanVitreo-Retinal Medical Group, CA6,112 citations
14David CallananAviceda Therapeutics, TX5,919 citations
15Raj MaturiIndiana University School of Medicine, IN5,805 citations
16Sharon FekratDuke University, NC5,408 citations
17Arshad KhananiSierra Eye Associates, NV5,354 citations
18Anne FungPacific Eye Associates, CA4,407 citations
19Susanna ParkUniversity of California, Davis, CA3,282 citations
20Dilsher DhootCalifornia Retina Consultants, CA2,541 citations
21David EichenbaumRetina Vitreous Associates of Florida, FL2,524 citations

Most NIH awards

NIH awards on the person's record in NIH RePORTER, across all of their funded work, among the people with at least two registered trials in this indication. 13 of the 361 people tagged to this indication have at least 2 registered trials in it and this count on record; the 13 highest are listed. Source: NIH RePORTER.

#Expertawards
1David BrownTX13 awards
2Peter CampochiaroWilmer Eye Institute, MD13 awards
3Jeremy KeenanUniversity of California, San Francisco, CA12 awards
4Scott CousinsDuke Medical Center, NC8 awards
5Paul BernsteinJohn A. Moran Eye Center, UT7 awards
6Neil BresslerWilmer Eye Institute, MD6 awards
7Richard RosenNY1 award
8Robert SnyderAZ1 award
9Robert AveryNM1 award
10Karl CsakyRetina Foundation of the Southwest, TX1 award
11Susanna ParkUniversity of California, Davis, CA1 award
12Priyatham MettuDuke Eye Center, NC1 award
13David CallananAviceda Therapeutics, TX1 award

Most congress contributions

Congress abstracts and presentations attributed to the person and verified by DOI, across every meeting the directory tracks, among the people with at least two registered trials in this indication. 3 of the 361 people tagged to this indication have at least 2 registered trials in it and this count on record; the 3 highest are listed. Source: Congress abstracts, DOI-verified.

#Expertcontributions
1Charles WykoffRetina Consultants of Texas, TX1 contribution
2David EichenbaumRetina Vitreous Associates of Florida, FL1 contribution
3Allen HoWills Eye Hospital, PA1 contribution

Emerging

11 of the 361 carry the Emerging flag: publication and trial activity rising over the recent three years, in the top ten percent for growth among specialty peers at a similar career stage. Listed A to Z, not ranked; the flag is a yes or nothing, never a score. How the flag is computed.

Baseer AhmadMedical College of Wisconsin, WI
Robert BhisitkulUniversity of California, San Francisco, CA
Nikhil BommakantiPA
Jordan DeanerThomas Jefferson University, PA
Ghassan GhorayebWest Virginia University, WV
Michael ProWills Eye Hospital, PA
Rithambara RamachandranMI
Landon RohowetzUniversity of Miami, FL
Ramin SchadluAZ
Jason SlakterNYU Grossman School of Medicine, NY
Robert VittiRegeneron, NJ

How these tables are computed

The cohort is every profile in the directory tagged to Macular Degeneration (AMD), from the person's registered trials and published research. Only indications with at least 200 tagged people get a page; a smaller cohort would say more about the tag than about the people in it. Each table sorts the cohort by one count, highest first, with no weighting, no blending and no editorial pass. Ties are broken by the profile's stable internal id so the same counts always give the same order. A person with no count on record is left out of that table, not ranked last.

Citations, NIH awards and congress contributions are counts over a person's whole record, not their work in this indication alone, so those three tables are limited to the indication's investigators: people with at least 2 registered trials in it. Without that rule the most cited people in a cohort are the ones whose careers span many diseases, which is a fact about their careers, not about this field. The registered-trials table is the indication-scoped count itself and has no such limit.

The counts are recomputed on every publish and the page carries the date of the publish it was built from. Previous editions are superseded, not archived.

What is deliberately absent

Reported industry payments are on every profile but are not a table here: a count of payers is a fact, and ranking people by it reads as a judgment. Prescribing volume is part of the paid workspace. The directory's influence tier is a judgment and never orders a public page. Sources and methodology.

Filter, sort and open every Macular Degeneration (AMD) profile in the directory